ACADIA derivative settlement preliminarily approved; governance reforms, $1.5M fees

ACADIA PHARMACEUTICALS INC

Court granted preliminary approval on Aug 24, 2026; final hearing set Jan 13, 2027 in San Diego.
Settlement requires maintaining corporate governance reforms for at least 4 years; no stockholder cash payments.
Stockholders' counsel to receive $1.5M in fees; service awards up to $5,000 each, court-approved.
Derivative claims trace to alleged misstatements on Nuplazid sNDA; FDA CRL in Apr 2021 cut shares >45% and 17%.
Objections due Dec 23, 2026; claims are derivative, not class action, and release all related demands.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.